Effect of empagliflozin when added to insulin in patients with type 2 diabetes and high cardiovascular (CV) risk: results from EMPA-REG OUTCOME

被引：0
作者：
Jurisic-Erzen, D. [1 ]
Johansen, O. [2 ]
George, J. [3 ]
Mattheus, M. [3 ]
Zinman, B. [4 ,5 ]
Inzucchi, S. [6 ]
机构：
[1] Univ Hosp Ctr Rijeka, Rijeka, Croatia
[2] Boehringer Ingelheim Norway KS, Asker, Norway
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[4] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[5] Univ Toronto, Div Endocrinol, Toronto, ON, Canada
[6] Yale Univ, Sch Med, Endocrinol Sect, New Haven, CT USA
来源：
DIABETOLOGIA | 2016年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
732
引用
收藏
页码：S349 / S349
页数：1
相关论文
共 50 条
  • [31] Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG
    Ryden, Lars
    Shahim, Bahira
    Mellbin, Linda
    CLINICAL THERAPEUTICS, 2016, 38 (06) : 1279 - 1287
  • [32] Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME
    Inzucchi, Silvio E.
    Khunti, Kamlesh
    Fitchett, David H.
    Wanner, Christoph
    Mattheus, Michaela
    George, Jyothis
    Ofstad, Anne Pernille
    Zinman, Bernard
    DIABETES, 2019, 68
  • [33] Consistent cardiovascular (CV) benefits from empagliflozin across the spectrum of CV risk factor control: post hoc analysis from EMPA-REG OUTCOME
    Inzucchi, S. E.
    Khunti, K.
    Fitchett, D. H.
    Wanner, C.
    Mattheus, M.
    George, J. T.
    Ofstad, A.
    Zinman, B.
    DIABETOLOGIA, 2019, 62 : S328 - S328
  • [34] Effect of empagliflozin on heart failure outcomes in subgroups by age: results from EMPA-REG OUTCOME
    Monteiro, P.
    Schaper, N.
    Clark, D.
    Hantel, S.
    Woerle, H. J.
    Inzucchi, S. E.
    Fitchett, D.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1191 - 1192
  • [35] Reduced progression of kidney disease with empagliflozin: results from EMPA-REG OUTCOME
    Wanner, C.
    Inzucchi, S.
    Lachin, J. M.
    Fitchett, D.
    von Eynatten, M.
    Mattheus, M.
    Johansen, O. E.
    Woerle, H. J.
    Broedl, U. C.
    Zinman, B.
    DIABETIC MEDICINE, 2017, 34 : 80 - 81
  • [36] EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE: RESULTS FROM EMPA-REG OUTCOME
    Lee, Dae Wook
    Monteiro, Pedro
    Clark, Douglas
    Hantel, Stefan
    Woerle, Hans J.
    Inzucchi, Silvio E.
    Fitchett, David
    JOURNAL OF HYPERTENSION, 2016, 34 : E520 - E520
  • [37] Effect of empagliflozin on heart failure outcomes in subgroups by age: results from EMPA-REG OUTCOME
    Monteiro, P.
    Schaper, N.
    Clark, D.
    Hantel, S.
    Woerle, H. -J.
    Inzucchi, S. E.
    Fitchett, D.
    DIABETOLOGIA, 2016, 59 : S534 - S534
  • [38] Effect of Empagliflozin on Heart Failure Outcomes in Subgroups by Age: Results from EMPA-REG Outcome
    Monteiro, Pedro
    Schaper, Nicolaas
    Clark, Douglas
    Hantel, Stefan
    Woerle, Hans J.
    Inzucchi, Silvio E.
    Fitchett, David
    DIABETES, 2016, 65 : A291 - A291
  • [39] Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial
    Lund, S. S.
    McGuire, D. K.
    Zinman, B.
    Inzucchi, S. E.
    Anker, S. D.
    Wanner, C.
    Kaspers, S.
    George, J. T.
    Elsasser, U.
    Woerle, H. J.
    Fitchett, D.
    DIABETOLOGIA, 2018, 61 : S324 - S325
  • [40] Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial
    McGuire, D. K.
    Zinman, B.
    Inzucchi, S. E.
    Anker, S. D.
    Wanner, C.
    Kaspers, S.
    George, J. T.
    Elsasser, U.
    Woerle, H. J.
    Lund, S. S.
    Fitchett, D.
    EUROPEAN HEART JOURNAL, 2018, 39 : 1091 - 1091
12345